DC-CIK + S-1

DC-CIK + S-1 is a chemo-immunotherapy combination regimen evaluated by Capital Medical University for the treatment of advanced gastric cancer. S-1 is an oral fluoropyrimidine formulation consisting of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor that increases 5-FU plasma levels), and oteracil potassium (which reduces 5-FU-induced gastrointestinal toxicity). DC-CIK (Dendritic Cell-Cytokine Induced Killer) therapy is an autologous cell-based immunotherapy where patient-derived immune cells are activated and expanded ex vivo before re-infusion. The combination aims to leverage the direct cytotoxic effects of S-1 with the enhanced immune surveillance and non-MHC-restricted tumor-killing capacity of DC-CIK cells. Clinical studies conducted at the Capital Medical University Cancer Center have demonstrated that this combination improves disease control rates and survival outcomes in patients with advanced gastric cancer compared to S-1 monotherapy.

Brand names

TS-1TS1TS 1Teysuno

Other names

S-1-Capital Medical University-gastric cancerS1-Capital Medical University-gastric cancerS 1-Capital Medical University-gastric cancerDC-CIK plus S-1Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy